Genmab A (GMAB) Current Leases (2019 - 2026)
Genmab A's (GMAB) quarterly Current Leases came in at $125.0 million in Q1 2026, down 3.1% YoY from $129.0 million in Q1 2025, and down 6.72% on a QoQ basis from $134.0 million in Q4 2025.
Genmab A (GMAB) Current Leases (2019 - 2026) Analysis & Trends
Genmab A (GMAB) has 6 years of Current Leases data on file, last reported at $125.0 million in Q1 2026.
- Quarterly Current Leases fell 3.1% year-over-year to $125.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $125.0 million (down 3.1% YoY) and the FY2025 annual result came in at $134.0 million, up 930.77% from the prior year.
- Current Leases fell to $125.0 million in Q1 2026, from $134.0 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $134.0 million in Q4 2025 to a low of $13.0 million in Q4 2023.
- A 4-year average of $96.0 million and a median of $126.0 million in 2025 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2025 — Current Leases surged 930.77% — and 2026, when it decreased 3.1%.
- Tracing GMAB's Current Leases over 4 years: stood at $13.0 million in 2023, then changed by 0.0% to $13.0 million in 2024, then surged by 930.77% to $134.0 million in 2025, then fell by 6.72% to $125.0 million in 2026.
- The last three Current Leases figures came in at $125.0 million (Q1 2026), $134.0 million (Q4 2025), and $126.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | 18.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.00 Mn |
| Mar 31, 2026 | 125.00 Mn |
| Dec 31, 2025 | 134.00 Mn |
| Sep 30, 2025 | 126.00 Mn |
| Jun 30, 2025 | 132.00 Mn |
| Mar 31, 2025 | 129.00 Mn |
| Dec 31, 2024 | 13.00 Mn |
| Dec 31, 2023 | 13.00 Mn |
| Sep 30, 2020 | 295.00 |
| Dec 31, 2019 | 155.00 |
| Sep 30, 2019 | 157.61 Mn |